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Introduction 
Helicobacter pylori, a gram-negative 
bacterium found on the luminal surface of 
the gastric epithelium, was first isolated by 
Warren and Marshall in 1983.1 Infection 
with Helicobacter pylori has been 
recognized as a public health problem 
worldwide.2  The prevalence of peptic ulcers 
in patients seropositive for H. pylori is seven 
times greater than in those who are 
seronegative.3  
Before the discovery of H. pylori, 
gastroduodenal ulcer healing was achieved 
with the administration of H2-blockers or 
proton pump inhibitors (PPIs) for at least 
four weeks.4 At present, H. pylori 
eradication therapy is indicated in 
gastroduodenal ulcer disease. Recent 
international consensus statements have 
concluded that H. pylori is a causal factor in 
peptic ulcer disease and a Group 1 
carcinogen in humans and all patients with 
peptic ulcer associated with H. pylori 
infection should receive eradication 
therapy.5  
The treatment of Helicobacter pylori 
remains a challenging clinical problem 
despite extensive research over the last 25 
years. PPI-based triple therapy, with a 
proton pump inhibitor, clarithromycin 
(CAM), and either amoxicillin (AMPC) or 
metronidazole, is a widely-recommended 
eradication therapy.6  Prevalence of H. 
pylori resistance to metronidazole is 
approximately 25%.7 PPI-based triple 
therapies have shown efficacy in various 
clinical trials from different geographic 
areas.8    Triple therapy  using a PPI with cla- 
 
rithromycin   and  amoxicillin  or  metro-
nidazole given twice daily remains the 
recommended first choice treatment. 
 
Diagnosis  
Endoscopy. Endoscopy is performed at 
baseline, upon completion of ulcer 
treatment, and one month after completion 
of ulcer treatment to confirm the state of the 
ulcer.  
Histologic examination. All histologic 
examinations for the diagnosis of H. pylori 
infection should be carried out at baseline 
and one month after the completion of the 
ulcer treatment. Biopsies should be obtained 
from the two sites of the greater curvature of 
the antrum and the greater curvature of the 
upper corpus. The biopsies should be fixed 
in formalin and slides prepared with 
hematoxylin-eosin and Giemsa stains. The 
bacterial density should be categorized as 
none, mild, moderate, marked, or judgment 
impossible.  
 
Gastric Ulcer 
The inflammation of the gastric mucosa 
induced by the infection is most pronounced 
in the non-acid-secreting antral region of the 
stomach and stimulates the increased release 
of gastrin.9  The increased gastrin levels in 
turn stimulate excess acid secretion from the 
more proximal acid-secreting fundic 
mucosa, which is relatively free of 
inflammation.10  The increased duodenal 
acid load damages the duodenal mucosa, 
causing ulceration and gastric metaplasia. 
The metaplastic mucosa then can become 
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colonized by H. pylori, which may 
contribute to the ulcerative process.  
Eradication of the infection provides a 
long-term cure of duodenal ulcers in more 
than 80% of patients whose ulcers are not 
associated with the use of nonsteroidal 
antiinflammatory drugs (NSAID).11 
NSAIDs are the main cause of H. pylori-
negative ulcers. Ulceration of the gastric 
mucosa is believed to be due to the damage 
to the mucosa caused by H. pylori. As with 
duodenal ulcers, eradicating the infection 
usually cures the disease, provided that the 
gastric ulcer is not due to NSAIDs.12 
 
H. pylori Treatment 
Various drug regimens are used to treat 
H. pylori infection. Most include two 
antibiotics plus a proton-pump inhibitor or a 
bismuth preparation (or both). The most 
commonly used initial treatment is triple 
therapy consisting of a proton-pump 
inhibitor plus clarithromycin and 
amoxicillin, each given twice per day for 7 
to 14 days. Metronidazole is used in place of 
amoxicillin in patients with a penicillin 
allergy.  
First-line treatment. Triple eradication 
therapy is the most commonly used 
treatment protocol in H. pylori eradication. 
Eradication of H. pylori removes the 
increased risk of developing actual ulcer 
disease.13 General agreement exists in that 
eradication of H. pylori infection with triple 
therapy including a PPI and two antibiotics 
for 7–10 days is the gold standard of 
treatment.14 In the recent triple combination 
studies, the eradication success declines over 
time.15 The preferred regimen internationally 
is triple therapy with a PPI, clarithromycin, 
and amoxicillin twice daily for 7-10 days.16 
Second-line treatment.  Second-line 
treatment includes bismuth, metronidazole, 
and tetracycline plus either a PPI or an H2 
receptor antagonist (H2RA).17 If a PPI is 
chosen, the regimen can be given for seven 
days. If an H2RA is used, however, 14 days 
are recommended.  A recent meta-analysis 
of 93 studies showed a higher rate of 
eradication with quadruple therapy that 
included both clarithromycin and 
metronidazole than with triple therapy that 
included both these agents in populations 
with either clarithromycin or metronidazole 
resistance. 18 
 
Discussion 
Helicobacter pylori is an important cause 
of duodenal and gastric ulcers. Greater than 
90% of duodenal ulcers and 70% of gastric 
ulcers are associated with H. pylori.1 
Eradication of H. pylori is effective in 
healing ulcers and drastically reducing the 
ulcer recurrence, eliminating the need for 
maintenance therapy.19 Treiber et al.20  
found that successful H. pylori eradication 
induced a better response in peptic ulcer 
healing, regardless of diagnosis of duodenal 
or gastric ulcer. Several large-scale clinical 
trials and meta-analyses have demonstrated 
that the most common first-line therapies 
fail in up to 20% of patients.21 
Currently-recommended protocols in-
clude a 10-14 day treatment with: (1) a 
proton pump inhibitor (PPI) plus 
clarithromycin and amoxicillin, (2) a PPI 
plus clarithromycin and metronidazole, or 
(3) bismuth subsalicylate plus metronidazole 
and tetracycline.22 The recommended 
duration of triple therapy is typically 10 to 
14 days in the United States and 7 days in 
Europe.23  Triple therapy with a proton 
pump inhibitor, clarithromycin, and 
amoxicillin or metronidazole remains an 
appropriate first-line therapy.  
Another possible initial therapy in areas 
with a high prevalence of clarithromycin-
resistant H. pylori infection (i.e., >20%) is 
quadruple therapy comprising the use of a 
proton-pump inhibitor, tetracycline, 
metronidazole, and a bismuth salt for 10 to 
14 days.24   
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The choice of second-line treatment is 
influenced by the initial treatment. 
Treatment failure often is related to H. 
pylori resistance to clarithromycin or 
metronidazole (or both agents). 
Clarithromycin should be avoided as part of 
second-line therapy unless resistance testing 
confirms that the H. pylori strain is 
susceptible to the drug.25  If initial therapy 
did not include a bismuth salt, bismuth-
based quadruple therapy commonly is used 
as second-line therapy with eradication rates 
ranging from 57 to 95%.26-29 Quadruple 
therapies, therefore, usually are reserved for 
patients who have failed one or more 
courses of triple therapy.30  Some quadruple 
therapies are less costly and appropriate for 
patients in whom cost is a significant factor. 
Conclusions 
Helicobacter pylori is a very common 
disease with a broad spectrum of clinical 
symptoms and disorders.  A PPI, clarithro-
mycin, and amoxicillin or metronidazole 
remains an appropriate first-line therapy, 
provided that there is not a high local rate of 
clarithromycin resistance. A PPI used in 
combination with metronidazole and either 
amoxicillin or tetracycline is recommended 
in patients previously treated with a PPI, 
amoxicillin, and clarithromycin.  Eradication 
of H. pylori infection has the potential to 
reduce the risk of gastric cancer 
development. 
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